Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward

Sobia, Parveen; Archary, Derseree

doi:10.3390/vaccines9091001

Cited by 3 publications

(11 citation statements)

References 313 publications

(359 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results published in 2021 indicated that this BnAb was unable to prevent overall HIV-1 acquisition, but that in VRC01-sensitive HIV-1 isolates, BnAb prophylaxis was effective [43]. The VRC01-sensitive HIV-1 isolates were only ~30% of the strains in circulation [44]. These results suggest that the VRC01 suppressed early circulating strains, but the immune system eventually lost to evolving resistant viral variants.…”

Section: Broadly Neutralizing Antibodies In Passive Immunization Trialsmentioning

confidence: 99%

“…While studying how efficacious are BnAbs, it is important to assess their behavior in vitro, the administration of BnAbs via intravenous therapy is not a feasible drug delivery system for large populations. It may also have limited use if administered in combination of BnAbs in high-risk groups, but overall this is not feasible or sustainable method for HIV-1 prevention [44].…”

Section: Broadly Neutralizing Antibodies In Passive Immunization Trialsmentioning

confidence: 99%

“…A lineage-based vaccine is focused on the immunological pathways forming antibody lineages that generate BnAb [27]. Regardless of which design is used, both germline-based and lineage-based designs use the "reverse vaccinology" to drive the production of the BnAb [44,47].…”

Section: Promising Vaccine Strategies: General Broadly Neutralizing A...mentioning

confidence: 99%

“…Additional BnAb-based vaccines currently being assessed are eOD-GT8 60 mer (protein nanoparticle derived from the VRC01 CD4-binding site) and gene therapy through a recombinant adeno-associated virus-mediated (rAAV) construct containing HIV BnAb genes [44].…”

Section: Promising Vaccine Strategies: Eod-gt8 60mer and Gene Therapymentioning

confidence: 99%

“…This is an important finding, because it provides some evidence that stimulation of rare B-cell precursors is possible. Further study is needed to validate this approach and determine that it works consistently [44].…”

Section: Promising Vaccine Strategies: Eod-gt8 60mer and Gene Therapymentioning

confidence: 99%

See 4 more Smart Citations

Immune Response to HIV-1 Infection and Vaccine Development

Hargrave¹,

Mustafa²,

Hanif³

et al. 2023

Immunosuppression and Immunomodulation

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV)-1 infection represents an ongoing challenging public health epidemic. This is in part because of the socioeconomic burden on low-income countries, lack of access to highly active antiretroviral therapy and other medical treatment, and progression to acquired immunodeficiency syndrome (AIDS) over the course of years. To control or eradicate this virus, a prophylactic vaccine must be generated. Despite several decades of research, development, and clinical trials, there is not yet an effective immunization. This chapter focuses on unique aspects of the immune response to this infection, challenges of vaccine development, key clinical trials, and promising vaccine strategies.

show abstract

Section: Broadly Neutralizing Antibodies In Passive Immunization Trialsmentioning

confidence: 99%

Section: Broadly Neutralizing Antibodies In Passive Immunization Trialsmentioning

confidence: 99%

Section: Promising Vaccine Strategies: General Broadly Neutralizing A...mentioning

confidence: 99%

Section: Promising Vaccine Strategies: Eod-gt8 60mer and Gene Therapymentioning

confidence: 99%

Section: Promising Vaccine Strategies: Eod-gt8 60mer and Gene Therapymentioning

confidence: 99%

See 3 more Smart Citations

Immune Response to HIV-1 Infection and Vaccine Development

Hargrave¹,

Mustafa²,

Hanif³

et al. 2023

Immunosuppression and Immunomodulation

View full text Add to dashboard Cite

show abstract

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Alum,

Uti,

Ugwu

et al. 2024

Medicine

View full text Add to dashboard Cite

Antiretroviral therapy, also known as antiretroviral therapy (ART), has been at the forefront of the ongoing battle against human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDs). ART is effective, but it has drawbacks such as side effects, medication resistance, and difficulty getting access to treatment, which highlights the urgent need for novel treatment approaches. This review explores the complex field of HIV/AIDS treatment, covering both established alternative treatment modalities and orthodox antiretroviral therapy. Numerous reliable databases were reviewed, including PubMed, Web of Science, Scopus, and Google Scholar. The results of a thorough literature search revealed numerous therapeutic options, including stem cell transplantation, immunotherapy, gene therapy, latency reversal agents, and pharmaceutical vaccinations. While gene therapy has promise for altering cellular resistance to infection and targeting HIV-positive cells, immunotherapy treatments seek to strengthen the immune system’s ability to combat HIV. Latency reversal agents offer a promising method of breaking the viral latency and making infected cells vulnerable to immune system destruction or antiretroviral drugs. Furthermore, there is potential for improving immune responses against HIV using medical vaccinations. This review stresses the vital significance of ongoing research and innovation in the hunt for a successful HIV/AIDS treatment through a thorough examination of recent developments and lingering challenges. The assessment notes that even though there has been tremendous progress in treating the illness, there is still more work to be done in addressing current barriers and investigating various treatment options in order to achieve the ultimate objective of putting an end to the HIV/AIDS pandemic.

show abstract

Strategies for HIV-1 suppression through key genes and cell therapy

Sorokina,

Anchakova,

Dashinimaev

2023

Front. Med.

View full text Add to dashboard Cite

Human immunodeficiency virus type 1 (HIV-1) remains a significant challenge for global public health as limited therapeutic options are available for HIV-infected individuals receiving combination antiretroviral therapy. Additionally, individuals with HIV-1/acquired immunodeficiency syndrome (AIDS) complications have a reduced life expectancy. In recent decades, gene and cell-based strategies have shown promise in achieving a functional cure for HIV-1 infection. The outcomes of therapies with patients in Berlin and London have led to moderate optimism for a highly effective HIV-1 treatment. This review categorizes current strategies for HIV-1 treatment into RNA- and antibody-based therapies, cell and genome editing approaches, and methods for eradicating latent reservoirs. These findings demonstrate how the use of various anti-HIV-1 agents enhances our understanding of HIV-1 infection and may provide important insights for potential HIV-1 treatment.

show abstract

Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward

Cited by 3 publications

References 313 publications

Immune Response to HIV-1 Infection and Vaccine Development

Immune Response to HIV-1 Infection and Vaccine Development

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Strategies for HIV-1 suppression through key genes and cell therapy

Contact Info

Product

Resources

About